# DESCRIPTION

## FIELD OF THE INVENTION

- introduce allosteric agonists of CXCR4

## BACKGROUND INFORMATION

- describe CXCR4 and its role in HIV-1 therapy
- discuss limitations of current CXCR4 antagonists

## BRIEF DESCRIPTION OF THE DRAWINGS

- describe figures illustrating yeast expression system and chemotactic properties of agonists

## DETAILED DESCRIPTION

### Materials and Methods

- describe vector construction and yeast strains
- outline media preparation and library construction
- detail Î²-galactosidase assay and peptide/protein production
- describe antibodies, CXCR4 antagonists, and chemotaxis/flow cytometry assays

## Results

### Functional Expression of Human CXCR4 in Yeast.

- establish yeast assay for CXCR4 agonists

### Library Screening and Agonist Isolation.

- screen cDNA library for CXCR4 agonists

### CXCR4 Dependence of RSVM and ASLW Effect.

- test CXCR4 dependence of RSVM and ASLW peptides

### Peptide Assays.

- characterize chemotactic activity of RSVM and ASLW peptides

### Effect of AMD3100, T140, 12G5, and 44717.111.

- test effect of CXCR4 antagonists on RSVM and ASLW peptides

### Full-Length Mutants.

- characterize full-length SDF mutants with RSVM and ASLW sequences

### Flow Cytometry.

- analyze CXCR4 surface levels after peptide stimulation

## Discussion

### CXCR4 Activation.

- discuss CXCR4 activation mechanism

### Allosteric CXCR4 Agonists.

- discuss allosteric agonism on CXCR4

### Drug Development.

- discuss potential for allosteric agonist development

### Therapeutic Implications.

- discuss therapeutic potential of allosteric CXCR4 agonists in HIV treatment

## Acknowledgements

- acknowledge funding sources

